✨ Free AI Report
Eikon Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Eikon Therapeutics, Inc.
Research Preview

Eikon Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Founded in 2019 by a team of scientists including Nobel laureate Eric Betzig, Eikon is built on the premise that directly visualizing molecular events inside living cells can revolutionize how new medicines – especial...

Analyst-debate audio for Eikon Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Eikon Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Eikon Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Technology-enabled drug discovery with world-class oncology expertise and a validated discovery platform could establish a new...

Read the full analyst-debate transcript →
Industry Oncology Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Eikon Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Eikon Therapeutics, Inc. Overview

Pro stress-test →

Founded in 2019 by a team of scientists including Nobel laureate Eric Betzig, Eikon is built on the premise that directly visualizing molecular events inside living cells can revolutionize how new medicines – especially cancer treatments – are discovered. Eikon Therapeutics is a star-studded biotechnology startup that raised more than $1 billion in venture funding, and secured $381 million through an initial public offering in February 2026, selling over 21 million shares at $18 apiece, with shares beginning trading under the ticker symbol "EIKN."

Strategic Profile

Pro stress-test →

The company is run by a group of former Merck & Co. executives including ex-research chief Roger Perlmutter and one-time clinical development leader Roy Baynes. Eikon's unique drug discovery platform marries advanced live-cell imaging technology with therapeutic development, using super-resolution fluorescence microscopy and single-molecule tracking to observe how proteins and other drug targets move and interact within live cells in real time. Eikon is a late-stage clinical biopharmaceutical company focused on developing medicines for serious unmet medical needs, with an initial emphasis on oncology.

Competitive Landscape

Pro stress-test →

Eikon's PARP inhibitors in Phase 1 are designed to be more selective than similar, available drugs like Merck and AstraZeneca's Lynparza. The company operates in the increasingly competitive oncology space alongside established players like Merck, AstraZeneca, and Bristol Myers Squibb, but differentiates through its proprietary live-cell imaging discovery platform and in-licensed, clinical-stage assets. Direct competitors in the platform-based drug discovery space include companies leveraging AI, structural biology, and computational approaches to accelerate oncology development.

Industry Context

Eikon Therapeutics, Inc. operates in Oncology Drugs.

Key facts

Founded: 2019 · Headquarters: Hayward, US · Employees: N/A · Revenue: N/A · Market cap: $590.7M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Eikon Therapeutics, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Eikon Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

LynparzaPARP inhibitor for cancer→KeytrudaImmuno-oncology checkpoint inhibitor→OpdivoPD-1 checkpoint inhibitor for cancer→

Compare Eikon Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Eikon Therapeutics, Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Eikon Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Eikon Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Eikon Therapeutics, Inc. do this quarter?”
“Is Eikon Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Eikon Therapeutics, Inc. do?+
Founded in 2019 by a team of scientists including Nobel laureate Eric Betzig, Eikon is built on the premise that directly visualizing molecular events inside living cells can revolutionize how new medicines – especial...
What is Eikon Therapeutics, Inc.'s Cyborg Score?+
Eikon Therapeutics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Eikon Therapeutics, Inc.'s main competitors?+
Named competitors include Lynparza, Keytruda, Opdivo. The full competitive landscape is in the AskCyborg report.
How can I get the full Eikon Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Eikon Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Eikon Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.